A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.

被引：0

作者：

Weisel, Katja

Hungria, Vania T. M.

Radinoff, Atanas

Delimpasi, Sosana

Mikala, Gabor

Masszi, Tamas

Li, Jian

Capra, Marcelo

Matsumoto, Morio

Sule, Neal

Li, Mary

McKeown, Astrid

He, Wei

Bright, Shelley

Currie, Brooke

Boyle, Julia

Opalinska, Joanna

Dimopoulos, Meletios A.

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Clin Sao Germano, Sao Paulo, Brazil

[3] Univ Hosp Sveti Ivan Rilski, Sofia, Bulgaria

[4] Gen Hosp Evangelismos, Athens, Greece

[5] South Pest Cent Hosp, Natl Inst Haematol & Infect Dis, Budapest, Hungary

[6] Semmelweis Univ, Dept Internal Med & Haematol, Budapest, Hungary

[7] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China

[8] Hosp Mae Deus, Ctr Integrado Hematol & Oncol, Porto Alegre, RS, Brazil

[9] Shibukawa Med Ctr, Natl Hosp Org, Shibukawa, Japan

[10] GSK, Upper Providence, PA USA

[11] GSK, Stevenage, Herts, England

[12] GSK, Waltham, MA USA

[13] GSK, Rockville, MD USA

[14] GSK, London, England

[15] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8007

引用

页数：1